WO2006102653A3 - Methods and compositions for treating insulin resistance and obesity-induced diseases - Google Patents

Methods and compositions for treating insulin resistance and obesity-induced diseases Download PDF

Info

Publication number
WO2006102653A3
WO2006102653A3 PCT/US2006/011067 US2006011067W WO2006102653A3 WO 2006102653 A3 WO2006102653 A3 WO 2006102653A3 US 2006011067 W US2006011067 W US 2006011067W WO 2006102653 A3 WO2006102653 A3 WO 2006102653A3
Authority
WO
WIPO (PCT)
Prior art keywords
insulin resistance
obesity
induced diseases
modulate
gpr41
Prior art date
Application number
PCT/US2006/011067
Other languages
French (fr)
Other versions
WO2006102653A2 (en
Inventor
Jiayu Liao
Sheng Ding
Hugh Rosen
Peter G Schultz
Original Assignee
Irm Llc
Scripps Research Inst
Jiayu Liao
Sheng Ding
Hugh Rosen
Peter G Schultz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc, Scripps Research Inst, Jiayu Liao, Sheng Ding, Hugh Rosen, Peter G Schultz filed Critical Irm Llc
Publication of WO2006102653A2 publication Critical patent/WO2006102653A2/en
Publication of WO2006102653A3 publication Critical patent/WO2006102653A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

This invention provides novel methods for identifying compounds that are useful in modulating insulin signaling activities or treating insulin resistance and other obesity-induced diseases. The modulators are identified by screening test compounds for ability to modulate G protein coupled receptor GPR43 or GPR41. Such GPR43 or GPR41 modulators can be further examined for their activity in modulating insulin signaling (e.g., ameliorating insulin resistance). Pharmaceutical compositions comprising compounds that modulate GPR41 or GPR 43 receptor activity or expression level can be administered to a subject to modulate insulin signaling related activities, and to treat obesity-induced diseases or conditions including insulin resistance and diabetes.
PCT/US2006/011067 2005-03-24 2006-03-23 Methods and compositions for treating insulin resistance and obesity-induced diseases WO2006102653A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66510005P 2005-03-24 2005-03-24
US60/665,100 2005-03-24

Publications (2)

Publication Number Publication Date
WO2006102653A2 WO2006102653A2 (en) 2006-09-28
WO2006102653A3 true WO2006102653A3 (en) 2007-01-11

Family

ID=37024714

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/011067 WO2006102653A2 (en) 2005-03-24 2006-03-23 Methods and compositions for treating insulin resistance and obesity-induced diseases

Country Status (1)

Country Link
WO (1) WO2006102653A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006036688A2 (en) 2004-09-22 2006-04-06 Arena Pharmaceuticals, Inc. Gpr43 and modulators thereof for the treatment of metabolic-related disorders
WO2010030997A1 (en) * 2008-09-12 2010-03-18 The Washington University Regulating intestinal microbiota dependent signaling as a means to modulate body fat and/or weight loss
US9314444B2 (en) 2009-01-12 2016-04-19 Biokier, Inc. Composition and method for treatment of NASH
US9006288B2 (en) 2009-01-12 2015-04-14 Biokier, Inc. Composition and method for treatment of diabetes
AU2013290100A1 (en) 2012-07-11 2015-01-29 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040137517A1 (en) * 2000-12-22 2004-07-15 Andrews John Leon Method of screening for gpr40 ligands

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040137517A1 (en) * 2000-12-22 2004-07-15 Andrews John Leon Method of screening for gpr40 ligands

Also Published As

Publication number Publication date
WO2006102653A2 (en) 2006-09-28

Similar Documents

Publication Publication Date Title
WO2006084193A3 (en) System and methods for performing neurophysiologic assessments during spine surgery
ATE483976T1 (en) GFATS AS P53 PATHWAY MODIFIERS AND METHODS OF USE
EP2292220A3 (en) Composition and methods for increasing insulin sensitivity
WO2009038689A3 (en) Compositions and methods for diagnosis and treatment of type 2 diabetes
WO2006060753A3 (en) Diagnosis and treatment of alzheimer's disease
AR052071A1 (en) PROCEDURES TO MODULATE THE ACTIVITIES OF THE ACETILCOLINE NICOTINIC RECEPTOR ALFA 7
WO2006102653A3 (en) Methods and compositions for treating insulin resistance and obesity-induced diseases
WO2007008982A3 (en) Methods and composition for modulating foxo1 activity and insulin signaling
WO2010102253A3 (en) Compositions and methods for modulation of cell migration
WO2006017171A3 (en) Methods of diagnosing & treating obesity, diabetes and insulin resistance
WO2005124358A3 (en) Diagnosis and treatment of siglec-6 associated diseases
ATE433115T1 (en) TIMP-2 AS A TARGET/MARKER OF BETA CELL FAILURE
Hu et al. Laser doppler perfusion imaging of skin territory to reflect autonomic functional recovery following sciatic nerve autografting repair in rats
WO2008027379A3 (en) Indicators of sirtuin activity and methods of use thereof
WO2006010533A3 (en) Pancreatic polypeptide as target/marker of beta cell failure
WO2006009947A3 (en) Migfs as modifiers of the igf pathway and methods of use
WO2005016279A3 (en) Melks as modifiers of the rac pathway and methods of use
ATE495271T1 (en) COMPOSITIONS AND METHODS FOR DETECTING HISTAMINE-RELATED DISORDERS
WO2006031718A3 (en) Compositions and methods for modulating rank activities
WO2005072475A3 (en) Itpks as modifiers of the igfr pathway and methods of use
DE602005010712D1 (en) INSULIN PROMOTER FACTOR 1 AS TARGET / MARKER OF BETA CELL FAULT
WO2006116075A3 (en) Methods and compositions for inhibiting hiv infection using agents that modulate isopeptidase t activity
WO2006119888A3 (en) Butyrylcholinesterase as target/marker for insulin resistance
WO2006031930A3 (en) Modulation of xbp-1 activity for treatment of metabolic disorders
EP1723415A4 (en) Pdes as modifiers of the igfr pathway and methods of use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06739712

Country of ref document: EP

Kind code of ref document: A2